The pharmaceutical landscape for diabetes is changing, and transdermal GLP-1 delivery systems represent a exciting breakthrough. Unlike injections, this approach offers a less invasive way to provide GLP-1 therapies. These patches steadily release the drug through the epidermis offering a consist